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Background:  Edoxaban, an oral direct factor Xa inhibitor, is in phase 3 clinical development for stroke prevention in AF and treatment of VTE. 
P-gp, an efflux transporter, can prevent the systemic absorption of xenobiotics in the GI tract. Strong substrates for P-gp can competitively block the 
efflux of weaker substrates, thereby increasing their exposure. 
Methods:  Five drug-drug interaction studies with quinidine, amiodarone, atorvastatin, verapamil and digoxin, all known P-gp inhibitors/substrates, 
were conducted with edoxaban. In 3 open-label, randomized, 2-period, 2-treatment crossover studies, healthy volunteers received edoxaban 60 mg 
QD alone and in combination with quinidine (300 mg [N=42]), verapamil (240 mg [N=34]) or atorvastatin (80 mg [N=32]). Edoxaban 60 mg QD 
alone and in combination with amiodarone (400 mg [N=30]) was evaluated in an open-label, one-sequence crossover study, and with digoxin (0.25 
mg [N=48]) in an open-label, dual-treatment sequence, parallel-group study. Edoxaban PK (Cmax, AUC, Cmin) and PD (PT, INR, aPTT) parameters 
were compared for the combination vs edoxaban alone.
Results:  
Percent Changea in Exposure of Edoxaban With Concomitant Medications Relative to Edoxaban Alone
Concomitant Medication Cmax Cmin AUC
Quinidine 85.4% 16.2% 76.7%
Amiodarone 66.0% -23.8% 39.8%
Verapamil 53.3% 25% 52.7%
Atorvastatin -14.2% 11.9% 1.7%
Digoxin 15.6% 9.3% 9.5%
aBased on ratio of geometric least squares means (LSM).
Effects on PT, INR and aPTT were positively correlated with plasma edoxaban concentrations. Administration of the selected drugs with edoxaban 
appeared safe and well tolerated.
Conclusion: Edoxaban exposure and PD were increased by the coadministration of quinidine, amiodarone or verapamil due primarily to P-gp 
inhibition; no effect was observed for atorvastatin or digoxin.
